neu in livewire today. I think Hugh has it wrong and doesnt...

neu in livewire today. I think Hugh has it wrong and doesnt understand the stock sufficiently but interesting to see his comments.

Buy Hold Sell: 5 dogs of 2024 tipped to rebound in 2025

https://livewiremarketsptyltd.cmail20.com/t/j-l-guydjit-ikthhrddm-d/

Neuren Pharmaceuticals (ASX: NEU)

Henry Jennings (BUY): For me, it is a buy - still a buy. It has been an interesting story to say the least. It did have a huge run on the back of the cash pulling through to the bottom line after they did the deal with Daybue. But Acadia, which is their partner in the US, came under some pressure from a Hindenburg report that knocked them quite hard and they've struggled. Next year they have a new drug which has even more promise than Daybue, in NNZ-2591. A catchy title, I know.

Hans Lee: They thought really long about that name.

Henry Jennings: Didn't they. They all do. They're all the same. And I think we should get some pretty good news out of that. And also there's the worldwide expansion of Daybue as well, which I think is to come.

Hans Lee: Okay. Hugh, while the share price has gone up six times in five years, it's almost halved since January from $25 to 13. Is it a buy-hold-sell for you?

Hugh Dive (HOLD): Soft-hold. Henry, you must have rubber underpants as you'd need them to own this stock going from $9, to $23 and back to $13.

It treats a very small particular disease, which afflicts one in 10,000 females. They've done a great job in terms of monetizing that. There's a lot of cash on the balance sheet, but a lot of those royalty cash flows are going to develop the new drug. If the new drug doesn't work, there's no dividends, but just the volatility scares me.